Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Orano Med LLC
Novartis
Pfizer
AstraZeneca
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Novita Pharmaceuticals, Inc.
Eli Lilly and Company
Columbia University
Compugen Ltd
Hutchmed
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
National Cancer Institute (NCI)
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Minneamrita Therapeutics LLC
Lebanese University
Ohio State University Comprehensive Cancer Center
Genzada Pharmaceuticals USA, Inc.
Provectus Pharmaceuticals
Novartis
MacroGenics
MacroGenics
Novartis
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
Synermore Biologics Co., Ltd.
Montefiore Medical Center
West Virginia University
Qilu Pharmaceutical Co., Ltd.
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
AbbVie
National Institutes of Health Clinical Center (CC)
Northwestern University
AbbVie
Altor BioScience
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)